This document provides an overview of atopic dermatitis (AD), also known as eczema, including its clinical presentation, diagnosis, and treatment. It discusses Julia, a 7 month old female presenting with a rash. The diagnosis is AD based on her symptoms. Her treatment plan includes daily baths, frequent moisturizing, topical corticosteroids for flares, oral antihistamines, and food allergy testing found negative for egg and peanut. The document reviews the association between AD and food allergies and recommends against broad allergy testing in patients with eczema.
Dr. Maria Hordinsky provides an informative, straightforward presentation of everything you need to know about alopecia areata, including risks and benefits of current and evolving off-label treatment options. Dr. Hordinsky is Professor and Chair of the Department of Dermatology at the University of Minnesota and is recognized for her clinical expertise in alopecia areata.
Dr. Leslie Castelo-Soccio presented an overview of what parents need to know about alopecia areata in children and adolescents, including the differences between pediatric and adult patients, and the risks and benefits of current and evolving off-label treatment options. Dr. Castelo-Soccio is Assistant Professor of Pediatrics and Dermatology at the University of Pennsylvania School of Medicine and head of the Pediatric Hair Clinic and Director of Research in Pediatric Dermatology at the Children’s Hospital of Philadelphia. Her clinical and academic research focus is on pediatric hair disorders.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
hanifin and rajka criteria, entymology, definition of AD, atopy, etiopathogenesis of AD, genetics in AD, filaggrin, epidermal barrier dysfunction, atopic march, hygiene hypothesis, infantile phase of AD, childhood phase of AD, adult phase of AD, pityriasis alba, denne morgan folds, dirty neck appearence, nipple dermatitis, hanifin and rajka criteria, UK refinement of hanifin and rajka criteria, millenium criteria of AD, japanese dermatological association criteria, management of AD, wet wrap therapy,
Eczema (Atopic Dermatitis) Definition, clinical presentation, and managementSerena Hijazeen
In this presentation, there is a full description of eczema, steps to manage it as pharmacists, the factors that worsen the case, and when to refer to a physician
Pruritis in pregnancy by dr alka mukherjee dr apurva mukherjee nagpur m.s. indiaalka mukherjee
Pruritus is the leading dermatological symptom during pregnancy. Besides preexisting or acquired dermatoses, there are a number of pregnancy-specific dermatological diseases such as PEP (polymorphic eruption of pregnancy, previously named PUPPP), pemphigoid (herpes) gestationis, and pruritus gravidarum that are accompanied by severe itching and scratching. Because of potential effects on the fetus, the treatment of pruritus in pregnancy requires prudent consideration. The use of topical and systemic treatments depends on the underlying aetiology of pruritus and the stage and status of the skin. In general, emollients, topical anti-pruritics and topical corticosteroids appear to be the safest options for localised forms of pruritus in pregnancy whereas systemic treatments and/or UV phototherapy are adequate for generalized pruritus. Systemic corticosteroids and a restricted number of antihistamines may be administered in severe cases
Dr. Maria Hordinsky provides an informative, straightforward presentation of everything you need to know about alopecia areata, including risks and benefits of current and evolving off-label treatment options. Dr. Hordinsky is Professor and Chair of the Department of Dermatology at the University of Minnesota and is recognized for her clinical expertise in alopecia areata.
Dr. Leslie Castelo-Soccio presented an overview of what parents need to know about alopecia areata in children and adolescents, including the differences between pediatric and adult patients, and the risks and benefits of current and evolving off-label treatment options. Dr. Castelo-Soccio is Assistant Professor of Pediatrics and Dermatology at the University of Pennsylvania School of Medicine and head of the Pediatric Hair Clinic and Director of Research in Pediatric Dermatology at the Children’s Hospital of Philadelphia. Her clinical and academic research focus is on pediatric hair disorders.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
hanifin and rajka criteria, entymology, definition of AD, atopy, etiopathogenesis of AD, genetics in AD, filaggrin, epidermal barrier dysfunction, atopic march, hygiene hypothesis, infantile phase of AD, childhood phase of AD, adult phase of AD, pityriasis alba, denne morgan folds, dirty neck appearence, nipple dermatitis, hanifin and rajka criteria, UK refinement of hanifin and rajka criteria, millenium criteria of AD, japanese dermatological association criteria, management of AD, wet wrap therapy,
Eczema (Atopic Dermatitis) Definition, clinical presentation, and managementSerena Hijazeen
In this presentation, there is a full description of eczema, steps to manage it as pharmacists, the factors that worsen the case, and when to refer to a physician
Pruritis in pregnancy by dr alka mukherjee dr apurva mukherjee nagpur m.s. indiaalka mukherjee
Pruritus is the leading dermatological symptom during pregnancy. Besides preexisting or acquired dermatoses, there are a number of pregnancy-specific dermatological diseases such as PEP (polymorphic eruption of pregnancy, previously named PUPPP), pemphigoid (herpes) gestationis, and pruritus gravidarum that are accompanied by severe itching and scratching. Because of potential effects on the fetus, the treatment of pruritus in pregnancy requires prudent consideration. The use of topical and systemic treatments depends on the underlying aetiology of pruritus and the stage and status of the skin. In general, emollients, topical anti-pruritics and topical corticosteroids appear to be the safest options for localised forms of pruritus in pregnancy whereas systemic treatments and/or UV phototherapy are adequate for generalized pruritus. Systemic corticosteroids and a restricted number of antihistamines may be administered in severe cases
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
3. Learning Objectives:
1. To understand how to recognize and
diagnose atopic dermatitis
2. To learn the clinical presentation of atopic
dermatitis
3. To review common treatments for atopic
dermatitis
4. To review developing treatment for atopic
dermatitis in the pediatric population
5. To review the association with food
allergies.
4. Case: Julia 7 month old female
• Referred to clinic by PMD for evaluation of a
rash and to find the cause, concerned it is a food
allergy
• Rash started around 3mo and has worsened
over last 3 months
• Started on the cheeks initially but is spreading to
trunk
• Seems uncomfortable and itchy
• Has been told not to bathe every day as this will
make the skin worse
5. Case Report: Julia
• Mom has been moisturizing with Aveeno twice a
day
• Given Hydrocortisone 2.5% to use twice a day
sparingly and only for 1 week.
• Medication worked but mom was nervous to use
it again
• Rash seems to get worse if Julia is upset
• Rash seems worse if it is hot outside or if Julia is
hot
• Seems to have difficulty sleeping when the rash
is really bad
8. What is Atopic Dermatitis?
•Chronic pruritic inflammatory skin disease
•Affects about 13% of children and about 7% of
adults in the US alone
•Also known as eczema
•Often called the “itch that rashes”
9. What is Atopic Dermatitis?
•Exact cause is unknown
•Thought to be due to a “leaky” skin barrier
•Do know there is an association with the Filaggrin
gene and increased risk for AD
•Also some link to substances that contain proteins
called proteases – proteases break the link
between the skin cells and make the skin barrier
leaky
10. What is Atopic Dermatitis?
• Sensitization to environmental allergens and
food allergens commonly seen but is not a cause
• Is an allergic spectrum disorder as patients with
moderate to severe disease often have elevated
serum IgE
• About 70% patients have a positive family history
of atopic diseases
– Risk can increase to 3-5 fold if both parents have
atopic disease
11. Clinical Presentation of Atopic Dermatitis
• Presentation varies widely
• Childhood onset begins early in life
– About 50% in first year
– About 85% by age 5
• Can persist into adulthood in anywhere from 20-
50% of patients
• Can have adult onset
– Reported by about 26% of adult patients
12. Clinical Presentation of Atopic Dermatitis
• Dry skin and severe pruritis
• Erythematous maculo-papular rash
• Vesicles that can have exudate and crusting
(acute flare)
• Dry, scaly, excoriated patches (more chronic
lesions)
• Lichenification (chronic)
• Hyper/hypo-pigmentation
13. Clinical Presentation of Atopic Dermatitis
• Excoriations at various stages of healing
• Persistent fidgeting due to pruritis
• Irritability
• Insomnia due to pruritis at night
• Decreased concentration secondary to itching
and being uncomfortable
14. Clinical Presentation of Atopic Dermatitis
•In infants to around age 2: Commonly starts on face
and scalp. Sometimes on extensor surfaces.
– Typically spares the genitalia/diaper area
•Age 2 – teenager: Presents more on the flexor surfaces
– Typical antecubital fossa and popliteal fossa
presentation
– Volar aspect wrists, ankles, neck
•Adults: Continues on flexor surfaces and also on hands
15. Diagnosing Atopic Dermatitis
• Clinical diagnosis based on history and
presentation
• Rule out other dermatologic conditions
• Rule out rare immunodeficiency conditions such
as hyper-IgE syndrome and Omenn syndrome
– Eczema accompanied by other symptom such as
failure to thrive, skin abscesses, cutaneous viral
infection, chronic diarrhea
– In adults need to rule psoriasis and cutaneous T-cell
lymphoma
16.
17.
18.
19.
20.
21.
22.
23. Diagnosing Atopic Dermatitis
• Several sets of criteria have been developed
• Hanifin-Rajka (H-R) criteria considered the gold
standard
• United Kingdom Working Party (UKWP)
abridged version of H-R criteria, tends to work
better for pediatric diagnosis
• Not all allergist/dermatologist use a diagnosing
criteria
26. Treatments for Atopic Dermatitis
• Accepted for publication June 26, 2019
• Includes newer topical medications like
Crisaborole (Eucrisa)
27.
28. Treatments for Atopic Dermatitis
• Treatment is daily given the chronicity of the
disease
• Multifaceted
• Personalized to the patient and severity
• Often requires review at follow up visits to
ensure compliance
29. Treatments for Atopic Dermatitis
• Atopic Derm myth #1: Baths make AD worse.
• Every patient no matter severity gets daily care
of basic management (bath and moisturizing)
• Daily bath Soak and seal
– 15-20 minutes warm, clean water
– Infants/small kids place wash cloth over areas not under
water and continue to wet
– Older kids can do shower
– Soaps do not have to be done daily. If used, use at end and
rinse immediately then out of bath.
– Pat dry
– Apply emollients (Aquaphor or Vaseline)
30. Treatments for Atopic Dermatitis
•Recommend moisturizing in the morning and at
bedtime after bath.
•Should do at least 1 more time mid-
day/afterschool
•Can be done as needed
•Infants – easy to tell parents to do with diaper
changes
•Older patients can use non-fragranced lotion
(CeraVe, Aveeno, Cetaphil, Eucerin)
31. Treatments for Atopic Dermatitis
• Avoidance of triggers (allergens and irritants)
– Fragrances
– Wool
– Temperature extremes
– Foods
– Soaps/detergents
33. Treatments for Atopic Dermatitis
Topical Steroids
• Atopic Derm Myth #2: Use steroids sparingly and
only for 7 days and no more.
• Topical steroids applied twice a day to flare
• Use a thick layer of the medication
• Prefer ointment over creams/lotions
• Use lowest potency that still controls the symptoms
• Use until area clears then 2-3 more days
• Can use up to 14 days in a row before needing to
take a break
34. Treatments for Atopic Dermatitis
Topical Steroids
• In some patients with severe atopic derm can do
a daily preventive application of topical steroids
– Typically done under supervision of Allergist or
Dermatologist
• Safe to use in infants
• Side effect profile is mild if used appropriately
– Side effect of topical steroids discoloration of the
skin and thinning of the skin
– Minimal absorption systemically if used appropriately
35. Treatments for Atopic Dermatitis
Topical Calcineurin inhibitor
• Includes Pimecrolimus and Tacrolimus
• Approved in use for patients age 2 years and
older
• Popular for use on eyelid atopic dermatitis and
hand dermatitis
• Can use up to 14 days in a row
• Side effect profile is mild if used appropriately
– Most common side effect is redness initially at the
application site improves with use
– Can make you more photosensitive
36. Treatments for Atopic Dermatitis
Topical PDE4 inhibitiors
• Crisaborole (brand name Eucrisa)
• Approved December 2016
• Ages 2 and older
• Nonsteriodal topical ointment that inhibits PDE 4
(intracellular mediator of inflammation that
degrades cyclic adenosine monophosphate)
• Can be applied anywhere except in the eyes, in
the mouth, or vaginally
37. Treatments for Atopic Dermatitis
Topical PDE4 inhibitiors
• Applied twice a day
• No limitation in how long it can be used
• Side effect profile is mild
– Most common side effects include redness and pain at application
– In our clinic majority of patients who come in on this medication have
stopped if for these reasons
38. 2
FTU
3
FTU
4.5
FTU
6
FTU
(leg)
3
FTU
2.5
FT
U
2 FTU
(arm)
1.5 FTU
(leg)
3 FTU
(front)
2 FTU
(front)
1 FTU
(front)
1.5
FTU
1.5
FTU
2
FTU
2.5
FTU
(Face
& neck)
1 FTU
(hand,
both
sides)
7 FTU
(trunk,
including
buttocks,
front or
back)
3.5 FTU
(front)
5 FTU
(back)
3.5 FTU
(back)
1.5 FTU
(back) 1.5 FTU
(arm)
1 FTU
(arm)
3 FTU
(back)
Topical Ointment Amounts
2 FTU
(foot)
Adolescent/Adult
>12 years
Child
6–10 years
Child
3–5 years
Infant
1–2 years
Infant
3–6 months
1
FTU
Eichenfeld LF, et al. Pediatrics. 2015;136:554-65.
Photo courtesy of Dermnet NZ, https://www.dermnetnz.org/image-licence.
FTU (fingertip unit) = amount of ointment expressed from a tube with
a 5 mm diameter nozzle measured to the tip of the palmar surface of
an adult’s index finger (˜5 g).
1 FTU = adequate amount of ointment for a “thin and even” application
to an area of skin equal to ˜2 adult hands (fingers together).
39.
40. Treatments for Atopic Dermatitis
Additional Therapies
• Oral antihistamines to control itching
– Cetirizine can be used as young as 6 months old
– Hydroxyzine at bedtime to control itch and help sleep
• Topical and oral antibiotics as needed for
superinfection
• Wet wrapping: Intense moisture therapy
involving wrapping affected areas overnight for 5
nights
– https://www.nationaljewish.org/conditions/eczema-
atopic-dermatitis/eczema-treatment/wet-wrap-therapy
41. Treatments for Atopic Dermatitis
Additional Therapies
• Biologics:
– Newest medication approved for treatment of
moderate-severe atopic dermatitis
– Dupilumab (Brand name: Dupixent)
• Monoclonal antibody that targets IL-4 receptor alpha-chain
subunit common to IL-4 and IL-13
• Injectable medication
• Reduction of pruritis
• Reduction in symptoms of anxiety and depression
• Improvement in quality of life
• Approved for 12 years and older
• Done under supervision of Allergist and/or Dermatologist
42. Treatments for Atopic Dermatitis
Additional Therapies
• Bleach bathes
• Phototherapy
• Hospitalization for intense eczema care
• Systemic immunosuppressants
43. Atopic Dermatitis and Food Allergies
•Commonly see patients with AD have food
allergies but as discussed above it is not the cause
•Can be at increased risk for food allergies
•LEAP study – risk factors included severe eczema
– Increased risk of peanut allergy if not introduced early
•NIH study
45. Atopic Dermatitis and Food Allergies
• Broad panel serum IgE or skin prick testing is not
recommended in patients with eczema
• Broad panel testing can lead to unnecessary
food avoidances and potential development of
food allergies due to avoidances
• FARE blog post from December 2015 does a
great job discussing research
– http://www.foodallergy.org/about-fare/blog/new-
research-on-food-allergies-and-atopic-dermatitis
• History can help with difference between allergic
reaction and food triggered eczema
46. Back to baby Julia…
•Started daily eczema care plan including:
– Daily bath
– Frequent moisturizing with Vaseline or Aquaphor
– Topical Desonide to face/neck flare ups and topical
Triamcinolone to body flare ups
– Cetirizine in the morning as needed for itching and
Hydroxyzine at bedtime as needed for itching
•Once the eczema was controlled addressed food
allergy concerns
– Skin testing negative to egg and peanut
– Introduction at home
48. Sources
Fishbein, A, Silverberg, J, Wilson, E, Ong, P. Update on
Atopic Dermatitis: Diagnosis, Severity Assesment, and
Treatment Selection. The Journal of Allergy and Clinical
Immunology: In Practice.
https://doi.org/10.1016/j.jaip.2019.06.044
Weston, W, Howe, William. Atopic dermatitis (eczema):
Pathogenesis, clinical manifestations, and diagnosis.
https://www.uptodate.com/contents/atopic-dermatitis-eczema-
pathogenesis-clinical-manifestations
Photos property of Dermnetnz.org
49. Sources
Schneider, L, Tilles, S, Lio, P, et. al. Atopic Dermatitis: A
Practice Paramater Update 2012
https://www.aaaai.org/aaaai/media/MediaLibrary/PDF%20doc
uments/Practice%20and%20parameters/Atopic-Dermatitis-
2013.pdf